

01997.033600.4

## **PATENT APPLICATION**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  MARY COLLINS, ET AL.			Examiner: Fozia M. Hamud			
Application No.: 09/714,792			Group Art Unit: 1647			
Filed:	November 16, 2000	)				
For:	ANTIBODIES TO HUMAN IL-13bc AND METHODS OF THEIR USE IN INHIBITING IL-13 BINDING	) : )	September 10, 2004			
P.O. Bo	ssioner for Patents ox 1450 dria, VA 22313-1450					

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

١

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

## **CONCLUSION**

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

09/14/2004 AADQF01 00000007 09714792 01 FC:1806 180.00 QP We also enclose a check for the required fee of \$180.00 to cover the Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

Lawrence S. Perry

Registration No. 31,865 Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza

New York, New York 10112-3800

Facsimile: (212) 218-2200

LSP\ac

FORM PTO 1449 (modified U.S. D	ied) EPARTMENT OF CON	AMERICA PE	ATTY DOCKET NO. APPLICATION NO. 01997.033600.4 09/714,792								
LIST OF REF	ERENCES CITED BY	APPLICANT(S)	APPLICANT Mary Collins et al.								
		SEP 1 3 2004 2	FILING DATE November 16, 2000  GROUP 1647								
	<del> </del>	E. LART	U.S. PATENT DOCUMENTS								
*EXAMINÉR INITIAL	DOCUMENT NUMBÉR	DATE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
			·								
	-										
				ļ							
	T	F	OREIGN PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·	1						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT					
				+		<u>·</u>					
			S) (Including Author, Title, Date, Pertinent Pages, Etc.)								
	Husain, et al J. Cancer, V	., "Interleukin-13 ol. 92 (2001), pag	Receptor as a Unique Target for Ant es 168-175	I-Gliob	iastoma The	erapy", <i>Int.</i>					
	Barth, "hlL-13 PE38QQR NeoPharm", <i>Current Opinion in Investigational Drugs</i> , Vol. 2, No. 9 (2001), pages 1309-1313										
	Li, et al., "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein <i>in vitro</i> and <i>in vivo</i> in nude mice", <i>Protein Engineering</i> , Vol. 15, No. 5 (2002), pages 419-427										
	Husain, et al., "Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside", <i>Journal of Neuro-Oncology</i> , Vol. 65 (2003), pages 37-48										
	Mintz, et al., "Molecular targeting with recombinant cytotoxins of interleukin-13 receptor α2-expressing glioma", <i>Journal of Neuro-Oncology</i> , Vol. 64 (2003), pages 117-123										
EXAMINER DATE CONSIDERED											

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	: 1	OT	1	
		-		